Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report

Abstract

therapy designed to selectively deplete elevated and activated myeloid cells, and it has shown efficacy in patients with ulcerative colitis (UC) and Crohn' s disease. 4 The present case report is the first description of the induction of remission with GMA treatment for a patient with both active UC and COV-ID-19. The our ethics committee judged that this case report did not need institutional review board approval. However, the study was performed in according with the principle of Declaration of Helsinki and we had got the agreement of this study from the patient. Written informed consent was obtained. CASE REPORTThe patient was a 25-year-old male. He was diagnosed 3 months earlier with UC of the total colitis type. He was started on induction of remission with 3,000 mg of 5-aminosalicylic acid (5-ASA), which improved his symptoms but did not lead to remission. For this reason, the 5-ASA dose was increased to an extreme dose of 4,000 mg and budesonide foam was started

SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID

“…Patients with IBD who are being treated with immunosuppressive drugs are likely to have a higher risk of developing serious COVID-19, although studies have shown conflicting results. 30 An Italian study published at the beginning of the COVID-19 pandemic reported that among 79 IBD patients with COVID-19, the prognosis was not worse in those who received anti-TNF treatment. 31 According to data in Surveillance Epidemiology of Coronavirus under Research Exclusion (SECURE-IBD), an international COVID-19 database for patients with IBD, the incidence of severe COVID-19 is more common in patients receiving systemic steroids than in those receiving anti-TNF therapy.…”

“…Patients with IBD who are being treated with immunosuppressive drugs are likely to have a higher risk of developing serious COVID-19, although studies have shown conflicting results [ 30 ]. An Italian study published at the beginning of the COVID-19 pandemic reported that among 79 IBD patients with COVID-19, the prognosis was not worse in those who received anti-TNF treatment [ 31 ].…”